When people stop taking the semaglutide injection, they quickly gain back most of the weight they lost—only about 13 pounds of the original 40-pound loss stays off after a year.
Claim Context
Discontinuation of subcutaneous semaglutide 2.4 mg leads to substantial weight regain, with participants regaining 12.0 kg over 52 weeks after treatment cessation, resulting in a net weight loss of only 6.1 kg from baseline after 120 weeks.
“STEP 1 extension: BW in SMG group: week 0 → 68: −18.1 kg; week 68 → 120: +12.0 kg; week 0 → 120: −6.1 kg; BW in placebo group: week 0 → 68: -2.2 kg; week 68 → 120: +2.0 kg; week 0 → 120: 0 kg (regained full BW).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled magnitude of weight regain after discontinuation of semaglutide across all RCTs with washout periods.
A systematic review and meta-analysis of all RCTs with washout phases (≥48 weeks) comparing semaglutide 2.4 mg to placebo, pooling weight change from end-of-treatment to end-of-washout, including at least 4 trials with >1000 total participants.
Causal effect of discontinuation versus continuation of semaglutide on weight regain.
A double-blind RCT of 400 adults with obesity who achieved ≥10% weight loss on semaglutide 2.4 mg, randomized to continue semaglutide or switch to placebo for 52 weeks, with primary outcome: percentage weight regain from end-of-treatment nadir.
Real-world patterns of weight regain after semaglutide discontinuation in diverse populations over 5+ years.
A prospective cohort study of 2000 adults who discontinued semaglutide 2.4 mg after achieving weight loss, tracking weight change, lifestyle behaviors, and metabolic markers annually for 5 years.
Association between weight regain magnitude and baseline metabolic or behavioral factors.
A matched case-control study comparing 250 individuals with >15% weight regain after semaglutide discontinuation to 500 matched controls with <5% regain, assessing baseline insulin resistance, eating behaviors, and physical activity levels.
Prevalence of weight regain >10% among former semaglutide users at a single point in time.
A cross-sectional survey of 3000 adults who previously used semaglutide 2.4 mg, asking current weight, duration of use, and time since discontinuation to estimate proportion with >10% regain.